A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •Patients with symptomatic CNS metastases;
• •Patients who have a known history of hepatitis C or chronic active hepatitis B or a known diagnosis of HIV
• •Any significant ophthalmologic abnormality
• •Patients who have any severe and/or uncontrolled medical conditions
• •Significant gastrointestinal abnormalities,
• •Patients who have impaired cardiac function or clinically significant cardiac diseases,
• •Chemotherapy, biologic therapy, immunotherapy, radiotherapy or investigational agents within 5 half-lives or within 4 weeks (whichever is longer) prior to administration of the first dose of study drug on Day 1 or have not recovered from the side effects of such therapy;
• •Treatment with third generation EGFR inhibitors
• •Major surgery/surgical therapy for any cause within 4 weeks of Screening;